Internal Emails Show FDA, Industry Jointly Framed 'Cures' Device Language
FDA and the largest medical device lobbying group worked together to develop proposed legislative language for most of the medical device provisions included in the House-passed 21st Century Cures bill, one of the largest FDA reform bills to pass the House in recent years, and are developing a synchronized regulatory strategy for the Senate version, according to internal emails and documents obtained by Inside Health Policy through the Freedom of Information Act.
President Barack Obama’s nominee for FDA commissioner, who has come under fire for his past relationships with industry, was aware of the partnership between the agency and the device lobbying group on legislative proposals, according to the emails and documents, and attended meetings with the group along with FDA's acting commissioner and the device center director.
The agency defended the meetings with the device lobbying group as standard procedure and said that Congress requested technical assistance from FDA on the Cures legislation. And, while congressional sources claimed the practice of soliciting outside opinion on legislation was critical to the legislative process, sources off Capitol Hill said they were alarmed at the level of coordination between the agency and the device lobbying group and the amount of influence both parties had over the Cures legislation...
- Tags:
- Advanced Medical Technology Association (AdvaMed)
- Barack Obama
- breakthrough devices
- Center for Devices and Radiological Health
- Clinical Laboratory Improvement Amendments (CLIA)
- conflict of interest
- consumer watchdog group Public Citizen
- FDA commissioner
- FDA reform bills
- FDA’s premarket program for medical devices
- Food and Drug Administration (FDA)
- Freedom of Information Act (FOIA)
- health software
- House-passed 21st Century Cures bill
- humanitarian device exemption application
- in vitro diagnostics
- Innovation for Healthier Americans Act
- Janet Trunzo
- Jeff Shuren
- Joe Williams
- medical device provisions
- pharmaceutical drug lobby groups
- Robert Califf
- Stephen Ostroff
- Steve Ubl
- third-party quality system assessment
- Login to post comments